Agilent Technologies Inc. has opened a new life sciences instruments manufacturing facility in Singapore. The facility will produce the company’s LC/MS instruments for the global market.

“The opening of the LC/MS manufacturing facility marks a milestone in Agilent’s continued investment in Singapore, which began in 1970,” said Bill Sullivan, Agilent president and CEO. “Singapore is the ideal location for this facility as it will provide us with greater access to the life sciences instrument market in Asia. The new facility also will bring us closer to our customers, as the pharmaceutical and biopharmaceutical industries have become an important part of Singapore’s overall economy and investment strategy.”

“I am pleased that Singapore will be an integral part of Agilent’s global manufacturing network,” said Mr S Iswaran, Senior Minister of State for Trade & Industry and Education. “Life sciences companies can further tap Singapore as a base in Asia to drive business expansion and innovation for the region.”

“This expansion marks a major achievement and positions Agilent to better meet rising worldwide customer demand for LC/MS instruments,” said Nick Roelofs, president of Agilent’s Life Sciences Group. “The new facility reflects the company’s commitment to Singapore, its partners, and other stakeholders in the Asia Pacific region, as well as to the growing life sciences market worldwide.”

Agilent will produce the Agilent 6100 series Single-Quadrupole LC/MS, 6200 series Accurate-Mass Time-of-Flight LC/MS, 6400 series Triple Quadrupole LC/MS and the 6500 series Accurate-Mass Quadrupole Time-of-Flight LC/MS at the new facility.